Jasper Therapeutics (JSPR) Accumulated Depreciation (2022 - 2026)

Jasper Therapeutics has reported Accumulated Depreciation for 5 years, with the latest figure at $4.2 million in Q2 2026.

• On a quarterly basis, Accumulated Depreciation rose 10.43% year-over-year to $4.2 million in Q2 2026; TTM through Jun 2026 was $4.2 million, a 10.43% increase from a year earlier, with the FY2025 full-year figure at $4.8 million, up 26.45% from the prior year.
• Accumulated Depreciation was $4.2 million for Q2 2026 at Jasper Therapeutics, down from $4.8 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $4.8 million in Q4 2025, with the low at $1.4 million in Q4 2022.
• Average Accumulated Depreciation over 5 years is $3.1 million, with a median of $3.3 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Accumulated Depreciation soared 81.95% in 2023, then grew 8.84% in 2025.
• Over 5 years, Accumulated Depreciation stood at $1.4 million in 2022, then surged by 81.95% to $2.5 million in 2023, then jumped by 54.76% to $3.8 million in 2024, then rose by 26.45% to $4.8 million in 2025, then dropped by 12.46% to $4.2 million in 2026.
• The last three Accumulated Depreciation figures came in at $4.2 million (Q2 2026), $4.8 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.